Septerna (NASDAQ:SEPN) Shares Up 9.4% – Here’s What Happened

Septerna, Inc. (NASDAQ:SEPN) shares traded up 9.4% on Tuesday . The stock traded as high as $29.92 and last traded at $30.0890. 45,197 shares traded hands during trading, a decline of 84% from the average session volume of 279,577 shares. The stock had previously closed at $27.50.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on SEPN shares. Wall Street Zen downgraded Septerna from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 10th. Raymond James Financial started coverage on Septerna in a report on Friday, December 19th. They set a “strong-buy” rating and a $38.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a report on Thursday, January 22nd. Truist Financial assumed coverage on shares of Septerna in a report on Monday, December 15th. They set a “buy” rating and a $34.00 price target on the stock. Finally, JonesTrading initiated coverage on shares of Septerna in a research report on Tuesday, December 23rd. They issued a “buy” rating and a $43.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $33.83.

Septerna Trading Up 10.1%

The business has a fifty day moving average price of $26.52 and a two-hundred day moving average price of $21.32. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -20.05 and a beta of 3.86.

Hedge Funds Weigh In On Septerna

Several institutional investors and hedge funds have recently modified their holdings of SEPN. Group One Trading LLC raised its holdings in shares of Septerna by 111.8% during the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock worth $26,000 after acquiring an additional 8,955 shares in the last quarter. Global Retirement Partners LLC purchased a new position in Septerna in the fourth quarter valued at about $35,000. Russell Investments Group Ltd. acquired a new position in Septerna in the 3rd quarter worth about $36,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Septerna during the 4th quarter worth about $53,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Septerna during the 4th quarter worth about $61,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.